Lower exports hit Kyowa Kirin but erythropoietins strong
This article was originally published in Scrip
Executive Summary
Despite good growth for its mainstay erythropoietin products, Kyowa Hakko Kirin's (KHK) pharmaceutical sales slid by 12% to ¥52.2 billion ($553.0 million) in the first quarter to June 30th, hit mainly by a lower value of exports because of the strong yen.